-
公开(公告)号：US20170080071A1
公开(公告)日：2017-03-23
申请号：US15370615
申请日：2016-12-06
Applicant: Texas Tech University System
Inventor： Maurizio Chiriva-Internati
IPC: A61K39/00 , G01N33/574
CPC classification number: A61K39/0011 , A61K35/15 , A61K2039/5154 , A61K2039/572 , C07K14/47 , C07K14/705 , C07K16/3023 , C12N9/12 , G01N33/57423 , G01N33/57488 , G01N2333/47 , G01N2333/705 , G01N2333/912
Abstract: The present invention includes compositions and methods for the diagnosis and treatment of lung cancer with a recombinant tumor-associated antigen loaded antigen presenting cell that generates a cytotoxic T lymphocyte specific immune response to at least one of SP17, AKAP-4, or PTTG1 expressed by one or more lung cancer cells.
-
2.发明申请公开(公告)号：US20150247860A1
公开(公告)日：2015-09-03
申请号：US14714443
申请日：2015-05-18
Applicant: Texas Tech University System
Inventor： Maurizio Chiriva-Internati
IPC: G01N33/574 , A61K39/00
CPC classification number: G01N33/57434 , A61K39/0011 , A61K2039/5154 , A61K2039/572 , A61K2039/585 , C12Q1/6886 , C12Q2600/158 , G01N33/57484 , G01N2333/91205
Abstract: A method and composition for the diagnosis of and treatment of prostate cancer including a recombinant AKAP-4 tumor-associated antigen loaded antigen presenting cell that generates an AKAP-4 specific cytotoxic T lymphocyte specific for one or more prostate cancer cells.
Abstract translation: 一种用于诊断和治疗前列腺癌的方法和组合物，包括产生对一种或多种前列腺癌细胞特异的AKAP-4特异性细胞毒性T淋巴细胞的重组AKAP-4肿瘤相关抗原载体的抗原呈递细胞。
-
公开(公告)号：US20150157691A1
公开(公告)日：2015-06-11
申请号：US14561981
申请日：2014-12-05
Applicant: Texas Tech University System
Inventor： Maurizio Chiriva-Internati , Jose A. Figueroa , Everardo Cobos
IPC: A61K38/17 , G01N33/561 , A61K31/337
CPC classification number: A61K38/1732 , A61K31/337 , A61K48/00 , C07K14/4726 , G01N33/57449 , G01N2500/10 , A61K2300/00
Abstract: The present invention includes a method for the treatment of an advanced ovarian cancer, comprising: identifying a patient with advanced ovarian cancer; and administering to the patient an effective amount of truncated, dominant negative form of Galectin-3 sufficient to reduce the advanced ovarian cancer. In certain aspects, the truncated, dominant negative form of Galectin-3 is provided in an amount sufficient to reduce at least one of growth, motility, invasion, angiogenesis, or prevents Akt/NF-κB activation of the ovarian cancer.
Abstract translation: 本发明包括一种治疗晚期卵巢癌的方法，包括：鉴定晚期卵巢癌患者; 并向患者施用足够减少晚期卵巢癌的有效量的截短的，显性阴性形式的Galectin-3。 在某些方面，提供半数优势阴性形式的半乳凝素-3以足以减少生长，运动性，侵袭，血管发生或抑制卵巢癌的Akt / NF-κB活化中的至少一种的量。
-
公开(公告)号：US09744212B2
公开(公告)日：2017-08-29
申请号：US15017856
申请日：2016-02-08
Applicant: Texas Tech University System , MandalMed, Inc.
Inventor： Maurizio Chiriva-Internati , Everardo Cobos , Constance John
CPC classification number: A61K38/1732 , A61K31/407 , A61K31/69 , A61K38/05 , A61K38/07 , A61K45/06 , A61K2300/00
Abstract: The present invention provides a novel composition of matter useful for the treatment of neoplastic diseases. The novel composition is synergistic and comprised of galectin-3C in combination with a proteasome inhibitor, the combination having a pharmacologic activity greater than the expected additive effect of its individual components. Other embodiments of the invention provide novel synergistic compositions of galectin-3C with a proteasome inhibitor capable of reducing or overcoming resistance that develops to the proteasome inhibitor or reducing the adverse side effects from the proteasome inhibitor through increasing the therapeutic efficacy of lower doses.
-
公开(公告)号：US09518989B2
公开(公告)日：2016-12-13
申请号：US14178407
申请日：2014-02-12
Applicant: Texas Tech University System
Inventor： Maurizio Chiriva-Internati
IPC: A61K39/00 , G01N33/574 , C07K16/30 , C07K14/47 , C07K14/705 , C12N9/12 , A61K35/15
CPC classification number: A61K39/0011 , A61K35/15 , A61K2039/5154 , A61K2039/572 , C07K14/47 , C07K14/705 , C07K16/3023 , C12N9/12 , G01N33/57423 , G01N33/57488 , G01N2333/47 , G01N2333/705 , G01N2333/912
Abstract: The present invention includes compositions and methods for the diagnosis and treatment of lung cancer with a recombinant tumor-associated antigen loaded antigen presenting cell that generates a cytotoxic T lymphocyte specific immune response to at least one of SP17, AKAP-4, or PTTG1 expressed by one or more lung cancer cells.
Abstract translation: 本发明包括用重组肿瘤相关抗原加载的抗原呈递细胞诊断和治疗肺癌的组合物和方法，其产生对SP17，AKAP-4或PTTG1中的至少一种表达的细胞毒性T淋巴细胞特异性免疫应答 一个或多个肺癌细胞。
-
Patent Agency Ranking
6.发明申请Galectin-3 Inhibitor (Gal-3M) is Associated with Additive Anti-Myeloma and Anti-Solid Tumor Effects, Decreased Osteoclastogenesis and Organ Protection when Used in Combination with Proteasome Inhibitors 审中-公开Galectin-3抑制剂（Gal-3M）与添加抗骨髓瘤和抗固体肿瘤作用相关联，当与蛋白酶体抑制剂组合使用时，破骨细胞形成和器官保护减少公开(公告)号：US20160122408A1
公开(公告)日：2016-05-05
申请号：US14992334
申请日：2016-01-11
Applicant: Texas Tech University System
Inventor： Maurizio Chiriva-Internati , Jose A. Figueroa , Everardo Cobos
IPC: C07K14/47
CPC classification number: C07K14/4726 , A61K31/145 , A61K31/27 , A61K31/336 , A61K31/353 , A61K31/4015 , A61K31/407 , A61K31/427 , A61K31/5377 , A61K31/69 , A61K31/713 , A61K38/05 , A61K38/06 , A61K38/07 , A61K38/1732 , A61K45/06 , G01N33/5011 , A61K2300/00 , A61K31/365
Abstract: The present invention includes a method for the treatment of myeloma comprising identifying a patient with myeloma and administering to the patient a synergistic, effective amount of a truncated, dominant negative form of Gaicctin-3 and a proteasome inhibitor.
Abstract translation: 本发明包括用于治疗骨髓瘤的方法，包括鉴定患有骨髓瘤的患者，并向患者施用协同的有效量的截短，显性失活形式的Gaicctin-3和蛋白酶体抑制剂。
-
7.发明申请Galectin-3 Inhibitor (Gal-3M) is Associated with Additive Anti-Myeloma and Anti-Solid Tumor Effects, Decreased Osteoclastogenesis and Organ Protection when Used in Combination with Proteasome Inhibitors 审中-公开Galectin-3抑制剂（Gal-3M）与添加抗骨髓瘤和抗固体肿瘤作用相关联，当与蛋白酶体抑制剂组合使用时，破骨细胞形成和器官保护减少公开(公告)号：US20160122407A1
公开(公告)日：2016-05-05
申请号：US14992173
申请日：2016-01-11
Applicant: Texas Tech University System
Inventor： Maurizio Chiriva-Internati , Jose A. Figueroa , Everardo Cobos
IPC: C07K14/47
CPC classification number: C07K14/4726 , A61K31/145 , A61K31/27 , A61K31/336 , A61K31/353 , A61K31/4015 , A61K31/407 , A61K31/427 , A61K31/5377 , A61K31/69 , A61K31/713 , A61K38/05 , A61K38/06 , A61K38/07 , A61K38/1732 , A61K45/06 , G01N33/5011 , A61K2300/00 , A61K31/365
Abstract: The present invention includes a method for the treatment of myeloma comprising identifying a patient with myeloma and administering to the patient a synergistic, effective amount of a truncated, dominant negative form of Galectin-3 and a proteasome inhibitor.
Abstract translation: 本发明包括用于治疗骨髓瘤的方法，包括鉴定患有骨髓瘤的患者，并向患者施用协同的有效量的半衰期，显性失活形式的Galectin-3和蛋白酶体抑制剂。
-
8.发明申请CANCER TESTIS ANTIGEN SPERM PROTEIN 17 AS A TARGET FOR BREAST CANCER IMMUNOTHERAPY AND DIAGNOSIS 审中-公开癌症TESTIS抗原蛋白17作为乳腺癌的手段免疫和诊断公开(公告)号：US20160030539A1
公开(公告)日：2016-02-04
申请号：US14815330
申请日：2015-07-31
Applicant: Texas Tech University System
Inventor： Maurizio Chiriva-Internati
IPC: A61K39/00 , A61K9/127 , G01N33/574 , A61K45/06
CPC classification number: A61K39/0011 , A61K31/138 , A61K31/555 , A61K45/06 , A61K2039/5154 , A61K2039/5158 , G01N33/57415 , G01N2333/705 , G01N2800/52 , A61K2300/00
Abstract: The present invention includes compositions and methods for treating a breast cancer cell, a metastatic breast cancer cell, or a triple negative breast cancer cell comprising: identifying a subject in need for treatment for a breast cancer cell, a metastatic breast cancer cell, or a triple negative breast cancer cell; and administering a therapeutically effective amount of a formulation that leads to the presentation of an immunogenic SP17 protein or peptide antigen on an antigen presenting cell to activate T cells that are SP17-specific T cells, wherein the SP17-specific T cells impair the growth of the breast cancer cell, the metastatic breast cancer cell, or the triple negative breast cancer cell growth.
Abstract translation: 本发明包括用于治疗乳腺癌细胞，转移性乳腺癌细胞或三阴性乳腺癌细胞的组合物和方法，包括：鉴定需要治疗乳腺癌细胞，转移性乳腺癌细胞或 三阴性乳腺癌细胞; 以及施用治疗有效量的制剂，其导致在抗原呈递细胞上呈递免疫原性SP17蛋白或肽抗原以活化作为SP17特异性T细胞的T细胞，其中所述SP17特异性T细胞损害 乳腺癌细胞，转移性乳腺癌细胞或三阴性乳腺癌细胞生长。
-
公开(公告)号：US09970937B2
公开(公告)日：2018-05-15
申请号：US14714443
申请日：2015-05-18
Applicant: Texas Tech University System
Inventor： Maurizio Chiriva-Internati
IPC: A61K38/00 , G01N33/574 , C12Q1/68 , A61K39/00
CPC classification number: G01N33/57434 , A61K39/0011 , A61K2039/5154 , A61K2039/572 , A61K2039/585 , C12Q1/6886 , C12Q2600/158 , G01N33/57484 , G01N2333/91205
Abstract: A method and composition for the diagnosis of and treatment of prostate cancer including a recombinant AKAP-4 tumor-associated antigen loaded antigen presenting cell that generates an AKAP-4 specific cytotoxic T lymphocyte specific for one or more prostate cancer cells.
-
公开(公告)号：US20160250289A1
公开(公告)日：2016-09-01
申请号：US15017856
申请日：2016-02-08
Applicant: Texas Tech University System
Inventor： Maurizio Chiriva-Internati , Everardo Cobos , Constance John
IPC: A61K38/17 , A61K38/07 , A61K31/407 , A61K45/06 , A61K38/05
CPC classification number: A61K38/1732 , A61K31/407 , A61K31/69 , A61K38/05 , A61K38/07 , A61K45/06 , A61K2300/00
Abstract: The present invention provides a novel composition of matter useful for the treatment of neoplastic diseases. The novel composition is synergistic and comprised of galectin-3C in combination with a proteasome inhibitor, the combination having a pharmacologic activity greater than the expected additive effect of its individual components. Other embodiments of the invention provide novel synergistic compositions of galectin-3C with a proteasome inhibitor capable of reducing or overcoming resistance that develops to the proteasome inhibitor or reducing the adverse side effects from the proteasome inhibitor through increasing the therapeutic efficacy of lower doses.
Abstract translation: 本发明提供了可用于治疗肿瘤性疾病的新物质组合物。 该新型组合物是协同增效的，并且包含半乳凝素-3C与蛋白酶体抑制剂的组合，该组合具有大于其单独成分的预期加成效应的药理活性。 本发明的其它实施方案提供半抗原-3C与蛋白酶体抑制剂的新型协同组合物，其能够通过增加较低剂量的治疗功效降低或克服发展为蛋白酶体抑制剂的抗性或降低蛋白酶体抑制剂的不良副作用。
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.017 seconds)
